The lancet gastroenterology & hepatology publishes data from albireo's landmark pedfic 1 study of bylvay® (odevixibat) treatment in pfic

Boston, july 06, 2022 (globe newswire) -- albireo pharma, inc. (nasdaq: albo), a rare liver disease company developing novel bile acid modulators, today announced that the lancet gastroenterology & hepatology published the results of the pivotal pedfic 1 trial, which evaluated bylvay® (odevixibat) for the treatment of progressive familial intrahepatic cholestasis (pfic). the study met both of its two primary endpoints, demonstrating that bylvay provided statistically significant improvements in pruritus severity scores and reductions in serum bile acid levels, with rapid, sustained, and consistent results. the full manuscript of the pedfic 1 study is available on the lancet gastroenterology & hepatology website.
ALBO Ratings Summary
ALBO Quant Ranking